Dr. Robert Howard Collins Jr., MD

Dr. Collins practices at William P. Clements Jr. University Hospital in Dallas, Texas, part of The University of Texas System.

Dr. Collins' NPI, 1851350979, was assigned on March 18, 2006. Dr. Collins graduated from UMKC School of Medicine in 1984. Dr. Collins holds Texas license G9580.

Dr. Collins' primary practice is William P. Clements Jr. University Hospital, at 6201 Harry Hines Blvd, Dallas, TX 75390 in Dallas County. The practice phone is (214) 633-5555.

Dr. Collins' primary practice is William P. Clements Jr. University Hospital in Dallas, Texas, part of The University of Texas System. The medical group on file is University of Texas Southwestern Medical Center. Dmand AI also links Dr. Collins to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Collins practices, 2 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Collins' primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Collins is board certified in internal medicine by the American Board of Internal Medicine. Dmand AI has Dr. Collins' licenses on file in 4 states: Texas, California, Oklahoma and Alabama.

Dmand AI lists chronic leukemia and lymphoma among the conditions Dr. Collins treats.

CMS data shows 369 Medicare services from Dr. Collins across 3 procedure codes in 2024, for 146 Medicare patients. Medicare paid $31,470 for them.

CMS counts 146 Medicare patients who saw Dr. Collins in 2024. The largest group is 65 to 74, with 61 patients. 75% of them have high blood pressure, and 75% have high cholesterol. Their average risk score is 2.48, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Collins' median patient age at 68, with 46% women.

In 2024, Dr. Collins wrote 675 Medicare Part D claims for 78 patients. 71% of them were for generic drugs. CMS names the drug for 442 of them, across 16 drugs with 11 or more claims each, at $1,931,027 in total drug cost. In 2023, CMS named 447 claims across 19 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 83 out of 100 for Dr. Collins for performance year 2024, reported as part of a group. Dr. Collins accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Collins as offering telehealth.

Dmand AI links 119 papers to Dr. Collins, published from 2006 to 2025. 2017 was the busiest year, with 10. The most frequent topics are Graft vs Host Disease, Leukemia, Myeloid, Acute and Bone Marrow Transplantation. Dr. Collins has published most often in Blood. Dr. Collins' most frequent co-authors are Weina Chen, MD, PhD, Prapti Arvind Patel, MD and Daniel Aaron Pollyea, MD.

Dmand AI links Dr. Collins to 12 clinical trials, 7 of them phase 2 studies. 2 are still active or recruiting. Conditions studied include Leukemia, Myeloid, Acute, Leukemia, Myeloid and Anemia, Refractory, with Excess of Blasts. OHSU Knight Cancer Institute sponsors the most, 3.

CMS Open Payments shows 11 general payments to Dr. Collins from 6 drug and device companies from 2016 to 2024. Compensation for serving as faculty or as a speaker for a medical education program make up the largest share, 63% of the total. Servier Pharmaceuticals LLC paid the most, $455. It also lists 3 research payments totaling $5,008 from 2016 to 2017.

Dmand AI lists 2 awards for Dr. Collins, most recently CMS Stage 1 EHR in 2012.

Dr. Collins graduated from UMKC School of Medicine in 1984.

Dr. Collins is in network with 24 carriers, including Elevance, Aetna and Blue Cross Blue Shield of Michigan. HMO plans come from the most carriers, 13. Check the plan with the practice before a visit.